Menu
Live
Market Overview
Live indices, gainers & losers
Market Pulse
AI-curated live updates
Market Movers
Top gainers & losers by cap
Market Signals
Value, momentum & analyst signals
Smart Money
Insider & congress trades
Hedge Funds
What 63 elite funds bought & sold
52-Week Highs
Stocks breaking out to new highs
52-Week Lows
Beaten-down stocks near support
High Beta
Stocks that move more than the market
Earnings Calendar
Upcoming earnings dates
Daily
Research
Invest
LIVE
Novartis AG
NVS
NYSE·Healthcare·Drug Manufacturers - General·Mkt cap $294.1B
$159.33
▲ +3.37%
View full research view
Our plain-language verdict, the thesis, risk factors, and what is changing about the business.
View research view52-Week Range
$112.34 - $170.46
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 24.5% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Robust R&D pipeline with focus on high-value therapeutic areas
- Strong intellectual property portfolio and patent protections
- Global manufacturing and distribution infrastructure
- Diversified revenue streams across multiple disease categories
Bear Case
1 risk
- Low volatility (beta 0.5).
Growth
Stable outlook
Increasing global demand for oncology and immunology treatments
Value
Attractively priced below sector peer average
Momentum
Stable
+0.1% over 3m
Quality
Excellent
Excellent business quality
Dividend
Solid
2.96% yield
Smart-money signal
Who's buying NVS right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Jul 21, 2026
Earnings recap unavailable for this period.
EPS surprise · last 4Q
Q1 26
$1.65
Q4 25
$1.26
Q3 25
$2.04
Q2 25
$2.07
Next: Jul 21, 2026
Revenue trend · last 8Q
—
—
—
—
+15%
+9%
-2%
-1%
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
$12.9B
$13.2B
$13.6B
$13.6B
$14.8B
$14.4B
$13.3B
$13.5B
Margins · last 8Q
Gross
74.4%
Operating
31.3%
Profit
23.3%
Wall Street consensus
1 analyst · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: Morgan Stanley · $170.00 · Mar 26, 2026
vs Industry
How NVS stacks vs Drug Manufacturers - General
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related
Peers & themes
Peers
No peer data available.
Themes
No themes assigned.